Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRalpha Peptide Vaccine With GM-CSF Following Cyclophosphamide in Triple Negative Breast Cancer
NCT03012100Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2017
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TPIV200 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Academic and Community Cancer Research United. Primary endpoint: Disease-Free Survival. Started Mar 2017; status: active, not recruiting.
02
Drugs
TPIV200
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03012100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012100.